Home infusion clinical services will be reimbursed in the Medicare Part B program starting on January 1, 2019. This new law, established by Congress as part of the Bipartisan Budget Act of 2018, provides for clinical services reimbursement for a limited set of home infusion drugs in the Medicare Part B Durable Medical Equipment benefit. Provisions of the law will affect home infusion providers and suppliers, home health agencies, and other companies in the industry.
This website was developed as a member-only resource to ensure companies have a full understanding of the regulation. It will provide detailed analysis of the new law, answers to frequently asked questions, and insight into the Centers for Medicare and Medicaid’s implementation of the law. The site will also provide information on efforts underway related to the Medicare Home Infusion Site of Care Act. This new transitional reimbursement law is the springboard to developing policy that may, in the future, include clinical service reimbursement for Medicare Part D infusion drugs.
ASP rates are released quarterly and can be found on the following CMS website.